Swedish lung cancer radiation study group: The prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3176-3182

  Holgersson, Georg ^a   Sandelin, Martin ^a   Hoye, Even ^b   Bergström, Stefan ^b   Henriksson, Roger ^c   Ekman, Simon ^a   Nyman, Jan ^d   Helsing, Martin ^f   Friesland, Signe ^e   Holgersson, Margareta ^a   Lundström, Kristina Lamberg ^a   Janson, Christer ^a   Birath, Elisabet ^f   Mörth, Charlotte ^a   Blystad, Thomas ^g   Ewers, Sven Börje ^f   Löden, Britta ^h   Bergqvist, Michael ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b GÄVLE HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h CENTRAL HOSPITAL   (Sweden)

Author keywords

Anaemia; Biomarker; Leukocytosis; Non small cell lung cancer; Prognosis; Thrombocytosis

Indexed keywords

BIOLOGICAL MARKER; HEMOGLOBIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENDER; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOSIS; BLOOD; CANCER STAGING; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SWEDEN;

ADULT; AGED; ANEMIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTOSIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN; THROMBOCYTOSIS;

EID: 84880266943     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0247-3     Document Type: Article

References (39)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl 8):S4-66.
2. Bolton WD, Rice DC, Correa AM, Hofstetter W, Komaki R, Mehran R et al. Influence of age on choice of therapy and surgical outcomes in patients with nonsmall cell lung cancer. Am Surg. 2009;75(7):598-603; discussion 4.
3. Spiro SG, Porter JC. Lung cancer-where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 2002;166(9):1166-96.
4. Spiro SG, Silvestri GA. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med. 2005;11(4):287-91.
5. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2(4):327-43. doi: 10.1097/01.JTO.0000263718.69320.4c.
6. Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol. 2008;1(4):406-12. doi: 10.1016/j.molonc.2007.12.001.
7. Chamogeorgakis T, Anagnostopoulos C, Kostopanagiotou G, Bhora F, Toumpoulis I, Georgiannakis E, et al. Does anemia affect outcome after lobectomy or pneumonectomy in early stage lung cancer patients who have not received neo-adjuvant treatment? Thorac Cardiovasc Surg. 2008;56(3):148-53. doi: 10.1055/s-2007-989455.
8. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Impact of preoperative hemoglobin level on survival of non-small cell lung cancer patients. Anticancer Res. 2008;28(3):1947-50.
9. MacRae R, Shyr Y, Johnson D, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol. 2002;64(1):37-40.
10. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001;92(9):2399-405. doi: 10.1002/1097-0142(20011101)92: 9<2399:AID-CNCR1588>3.0.CO;2-W.
11. Ferrigno D, Buccheri G. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis. 2003;59(3):193-8.
12. Thomson SP, Kessler JF, Miller TP. Leukocyte concentrations in discrimination of benign from malignant lung lesions. Am J Med. 1986;80(6):1035-40.
13. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2008;7(4):613-5. doi: 10.1510/icvts.2007.174391.
14. Gislason T, Nou E. Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma: an epidemiological study. Eur J Respir Dis. 1985;66(2):141-6.
15. Engan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncol. 1990;29(2):151-4.
16. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9(9):1826-30.
17. Aoe K, Hiraki A, Ueoka H, Kiura K, Tabata M, Tanaka M, et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration. 2004;71(2):170-3. doi: 10.1159/000076679.
18. Costantini V, Zacharski LR, Moritz TE, Edwards RL. The platelet count in carcinoma of the lung and colon. Thromb Haemost. 1990;64(4):501-5.
19. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006;107(4):781-92. doi: 10.1002/cncr.22049.
20. Maione P, Rossi A, Di Maio M, Gridelli C. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer. 2009;66(1):8-14. doi: 10.1016/j.lungcan.2009.02.022.
21. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9(9):1618-26.
22. Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, et al. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009;4(9):1117-25. doi: 10.1097/JTO.0b013e3181b27b33.
23. Mandrekar SJ, Northfelt DW, Schild SE, Foster NR, Bot B, Marks RS, et al. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. J Thorac Oncol. 2006;1(6):556-63.
24. Suda T, Miura Y, Mizoguchi H, Kubota K, Takaku F. A case of lung cancer associated with granulocytosis and production of colony-stimulating activity by the tumour. Br J Cancer. 1980;41(6):980-4.
25. Shijubo N, Inoue Y, Hirasawa M, Igarashi T, Mori M, Matsuura A, et al. Granulocyte colony-stimulating factor-producing large cell undifferentiated carcinoma of the lung. Intern Med. 1992;31(2):277-80.
26. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 2004;9(Suppl 5):31-40. doi: 10.1634/theoncologist.9-90005-31.
27. Vaupel P, Briest S, Hockel M. Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr. 2002;152(13-14):334-42.
28. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2001;18(4):243-59. doi: 10.1385/MO:18:4:243.
29. Teicher BA. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am. 1995;9(2):475-506.
30. Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood. 1984;63(1):55-63.
31. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med. 1981;95(5):636-41.
32. Gastpar H, Ambrus JL, Ambrus CM. Platelet cancer cell interaction in metastasis formation. Platelet aggregation inhibitors: a possible approach to metastasis prevention. Prog Clin Biol Res. 1982;89:63-82.
33. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. Anticancer Res. 2009;29(7):2687-90.
34. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-42. doi: 10.1056/NEJMoa1000678.
35. Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect. 1995;103(Suppl 8):131-42.
36. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110(7):1429-35. doi: 10.1002/cncr.22963.
37. Liu BQ, Peto R, Chen ZM, Boreham J, Wu YP, Li JY, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ. 1998;317(7170):1411-22.
38. Soo RA, Anderson BO, Cho BC, Yang CH, Liao M, Lim WT, et al. First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1102-10. doi: 10.1016/S1470-2045(09)70238-4.
39. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43. doi: 10.1016/S1470-2045(01)00486-7.